Fundamental Analysis of Abbott Laboratories - Growth / Value Index
ABT - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.103
Book Value in last 3 years is trending up
Tsr Value Index - Poor Score of 29.69
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 35.15 | 26.70 | 1.99 % | |
| Price to Book | 3.02 | 2.49 | -51.46 % | 4.81 |
| Price to Sales | 4.54 | 4.24 | -1.32 % | |
| Enterprise Value to EBITDA Multiple | 24.45 | 17.95 | 14.04 % |
ABT - Profitability Highlights
Profitability Analysis
Piotroski F Score - Good Value of 7.0
Excellent QoQ /QoQ FY EPS growth
Company Earning excess return
Company's Net Profit is increasing for last 5 Quarters
Steady Growth in EPS for last four quarters
Good Return On Capital Employed of 12.97
Good Return on Equity of 11.68% is achieved by the company
Good Net Margin of 12.92% is achieved by the company
Low Earning Yield of 3.17 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 10.10 | 18.90 | -4.31 % | 2.00 |
| Return On Asset | 7.03 | 9.31 | -0.953 % | 1.99 |
| Net Profit Margin | 12.92 | 15.88 | -3.25 % | 14.16 |
| Operating Profit Margin | 15.08 | 19.16 | -2.06 % | 16.46 |
| EBITDA Margin | 19.12 | 24.50 | -14.08 % | 14.16 |
Highlights
| Market Cap | 179907 M |
| Enterprise Value | 186798 M |
| Price/Book TTM | 3.02 |
| Outstanding Share | 1736.06 M |
| Float/ Outstanding Share | 99.42% |
| Dividend Yield | 2.00 % |
Share Holding
Guru Numbers
| Price/Graham No | 1.97 |
| Peter Lynch Ratio | -0.055 |
| Piotroski F Score | 7.0 |
| Altman Z Score | 494.76 |
| Sloan Ratio | -0.0122 |
| Peter Lynch Fair Value | 33.12 |
ABT - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 39959.00 M | 1.34 % | 1.65 % |
| Gross Profit | 21947.00 M | 0.110 % | 0.783 % |
| EBITDA | 7639.00 M | 12.93 % | 35.20 % |
| Net Profit | 5162.00 M | 1.95 % | 4.44 % |
| EPS | 2.95 | 1.95 % | NA |
ABT - Stability Highlights
Stability Analysis
Altman Z Score of 443.31 suggests good Stability
Debt to equity ratio has decreased and is lowest in last five years
Decreasing debt with Increasing revenue
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.457 | -9.31 % | 0.216 |
| Cash Ratio | 0.657 | -16.04 % | |
| Quick Ratio | 1.23 | -15.53 % | 1.23 |
| Shareholders Equity | 49.28 | 3.51 % | |
| Debt to EBITDA | 1.57 | 6.72 % |
Historical Valuation Ratios of Abbott Laboratories
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Abbott Laboratories
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Abbott Laboratories
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Abbott Laboratories
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)